Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation-Reference-Cited by-同舟云学术

Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation

Published:2020-10 Issue:10 Volume:15 Page:e174-e176
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dagogo-Jack Ibiayi^ORCID

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations;Sheikine;JCO Precis Oncol,2018

2. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol,2017

3. Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer;Dagogo-Jack;Clin Cancer Res,2019

4. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS;Yao;Nature,2017

5. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and Dabrafenib;Noeparast;Oncotarget,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC;Scientific Reports;2024-09-01

2. Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation;IJU Case Reports;2024-07-10

3. A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass;The Oncologist;2024-06-17

4. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer;Journal of the National Comprehensive Cancer Network;2024-04

5. Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review;Frontiers in Oncology;2024-03-27